HeartBeam (BEAT)
Builds cable-free ECG technology that synthesizes a 12-lead reading for arrhythmia assessment.
Something off on this page? Send us feedback.
Develops a portable, cable-free 3D ECG platform that synthesizes a 12-lead ECG for arrhythmia assessment. The company is moving from direct device sales toward licensing its cardiac-signal technology to established partners.
Captures ECG signals in three non-coplanar directions and synthesizes them into a 12-lead ECG. The portable, cable-free platform is intended for clinician-directed assessment outside medical facilities, with FDA clearance limited to arrhythmia assessment.
In 2026, HeartBeam announced a move beyond direct medical-device sales, prioritizing licensing to established partners such as ECG equipment makers, health systems, and wearable companies. Initial commercialization has included a staged rollout planned under a letter of intent with ClearCardio, rather than a completed customer agreement.
Heart-attack detection remains outside the cleared and commercially available indication in the United States.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | H.C. Wainwright | Downgrade | ||
| Jul 14, 2026 | Maxim Group | Target | Target: — | Target: $2 |
| Dec 11, 2025 | H.C. Wainwright | Target | Target: $2.50 | Target: $5.50 |
| Dec 10, 2025 | UBS | Target | Target: — | Target: $5.50 |
| Dec 8, 2025 | H.C. Wainwright | Target | Target: — | Target: $2.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.7M · Total debt $0 · Total assets $10.6M · Shareholders' equity $8.2M
- Revenue
- $0
- Operating income
- −$5.1M
- Net income
- −$5.0M
No dividends on record.
| Institutions | 14.40% | 8.11M shares | |
|---|---|---|---|
| 42 holders · as of Jun 30, 2026 | |||
| Insiders | 17.20% | 9.69M shares | |
| 10 holders · as of Aug 13, 2026 | |||
| Other | 68.40% | 38.54M shares | |
| remainder | |||
56.35M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Branislav VajdicInsiderdirector, officer: President | 7.05% | 3.97M | filed Jul 24, 2026 |
Mark E. StromeInsiderdirector | 6.68% | 3.76M | filed Aug 13, 2026 |
Vanguard Capital Management LLCInstitution | 3.79% | 2.14M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.75% | 987,837 | as of Jun 30, 2026 |
Corsair Capital Management, L.P.Institution | 1.62% | 912,500 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 16, 2026 | Richard Ferrari | director | +120,000 | $0.8000 |
| Apr 16, 2026 | Mark E. Strome | director | +750,000 | $0.8000 |
| Apr 16, 2026 | Marga Ortigas-Wedekind | director | +25,000 | $0.8000 |
| Apr 16, 2026 | Robert Paul ENO | officer: President | +12,500 | $0.8000 |
| Apr 16, 2026 | Branislav Vajdic | director | +31,250 | $0.8000 |
- GE HealthCare
Ambulatory ECG, Holter, and cardiac-management platform overlap.
- Philips (ADR)
Clinical and ambulatory ECG monitoring from Holter to ePatch.
- iRhythm
Long-term patch ECG monitoring and arrhythmia-analysis service.
- Apple
Consumer wearable ECG and AFib-oriented rhythm notifications.
- Alphabet Class C
Pixel Watch ECG and irregular-heart-rhythm features.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| HeartBeam | $0.3971 | −8.44% | $24.1M | — | — | — | — |
| GE HealthCare | $66.01 | −0.39% | $29.93B | 19.2 | 12.7 | 1.5 | +5.8% |
| Philips (ADR) | $24.48 | −1.98% | $24.41B | 18.9 | 12.8 | 1.2 | −2.8% |
| iRhythm | $114.57 | +3.66% | $3.63B | — | 229.5 | 4.4 | +20.1% |
| Apple | $337.02 | −0.80% | $4.99T | 38.9 | 36.3 | 10.7 | +16.4% |
| Alphabet Class C | $335.65 | −3.39% | $4.22T | 17.4 | 25.0 | 9.5 | +24.2% |
| Median | 19.0 | 25.0 | 4.4 | +16.4% |